Capstone Investment Advisors
IMNM icon

Capstone Investment Advisors’s Immunome IMNM Stock Holding History

Capstone Investment Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$321K Buy
+14,656
New +$326K ﹤0.01% 1347
2024
Q2 		– Sell
-42,300
Closed -$1.04M – 2261
2024
Q1 		$1.04M Buy
+42,300
New +$858K ﹤0.01% 1130

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Capstone Investment Advisors's IMNM Position: Q1 2026 in Review

Capstone Investment Advisors opened a new position in Immunome (IMNM) in Q1 2026: 14,656 shares worth $321K. The stake represents ﹤0.01% of the portfolio and ranks #1347 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in IMNM as recently as Q1 2024.

Capstone Investment Advisors first reported a position in IMNM in Q1 2024 and has held it in 2 quarters since. The position peaked at $1.04M in Q1 2024. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Capstone Investment Advisors held 14,656 shares of Immunome worth $321K as of Q1 2026.
  • Immunome was a new Capstone Investment Advisors position in Q1 2026.
  • Immunome made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #1347 holding.
  • Capstone Investment Advisors first reported a position in Immunome in Q1 2024 and has held it in 2 quarters since.
  • Capstone Investment Advisors's Immunome position peaked at $1.04M in Q1 2024.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.